IL6 supports long-term expansion of hepatocytes in vitro

Hepatocytes are very difficult to expand in vitro. A few studies have demonstrated that chemical cocktails with growth factors or Wnt ligands can support long-term expansion of hepatocytes via dedifferentiation. However, the culture conditions are complex, and clonal expansion of hepatic progenitors with full differentiation capacity are rarely reported. Here, we discover IL6, combined with EGF and HGF, promotes long-term expansion (>30 passages in ~150 days with theoretical expansion of ~10^35 times) of primary mouse hepatocytes in simple 2D culture, by converting hepatocytes into induced hepatic progenitor cells (iHPCs), which maintain the capacity of differentiation into hepatocytes. IL6 also supports the establishment of single hepatocyte-derived iHPC clones. The summation of the downstream STAT3, ERK and AKT pathways induces a number of transcription factors which support rapid growth. This physiological and simple way may provide ideas for cultivating previously difficult-to-culture cell types and support their future applications.

Liver is the primary metabolic organ in mammals. During homeostasis, the liver cells generally have a low turnover rate. However, liver exhibits robust regeneration following chemical, viral or mechanical injuries, attributing to the immediate proliferation of hepatocytes. After 2/3 partial hepatectomy (PHX) in mice, it takes only 1 week for the remaining liver to regenerate to the original size. Comparing to the robust proliferation capacity in vivo, adult hepatocytes have been proven to be extremely difficult to culture and expand without losing their hepatic characteristics in vitro. Due to the wide application of primary hepatocytes in drug toxicity and metabolism evaluation, and the potential use of hepatocyte cell therapy in liver diseases, to identify ways to expand hepatocytes in vitro is an urgent task.

It has been reported that hepatocyte replenishment following liver damage occurs via a reversible transition between hepatocytes and duct-like progenitor cells. In 2017, two studies opened up a new dimension in hepatocytes culture following this progenitor idea. One has reported that a cocktail of small molecules A-83-01 (inhibitor of TGF-β signaling), Y27632 (inhibitor of ROCK kinase) and CHIR99021 (activator of canonical Wnt pathway) can convert rat and mouse hepatocytes into hepatic progenitor cells (HPC) with high proliferative capacity. Another study has shown that a combination of five molecules A-83-01, Y27632, CHIR99021, S1P (sphingosine-1-phosphate) and LPA (lysophosphatidic acid) can expand mouse hepatocytes in vitro by promoting a reversible transition between hepatocytes and HPC. Interestingly, a study has reported the combination of TNFα, (a vital inflammatory cytokine in liver regeneration), A-83-01, Y27632 and CHIR99021 could promote mouse hepatocyte proliferation in 3D culture. After that, a protocol that enables large-scale expansion of human hepatocytes, by using Wnt3a protein with A-83-01 and Y27632 in low oxygen condition, has been reported. Recently more studies

1State Key Laboratory of Drug Research, National Center for Drug Screening, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 202203, China. 2School of Life Science and Technology, ShanghaiTech University, Shanghai 201210, China. 3University of Chinese Academy of Sciences, No.19 A Yuquan Road, 100049 Beijing, China. 4Department of Pharmaceutics, School of Pharmacy, Fudan University, Shanghai 201203, China. 5School of Pharmaceutical Science and Technology, Hangzhou Institute for Advanced Study, University of Chinese Academy of Sciences, Hangzhou 310024, China. 6School of Pharmaceutical Science, Nanchang University, Nanchang 330006, China. 7Shandong Laboratory of Yantai Drug Discovery, Bohai Rim Advanced Research Institute for Drug Discovery, Yantai 264117 Shandong, China. 8These authors contributed equally: Ren Guo, Mengmeng Jiang, Gang Wang, Bing Li. e-mail: xxie@simm.ac.cn
reported the culture of human fetal or adult hepatocytes using chemicals in combination with growth factors or conditioned medium in 2D or 3D conditions. These conditions (Supplementary Table 1) all involve the use of chemicals which do not exist in vivo. And clonal expansion from a single liver/hepatocyte progenitor cell with full differentiation capacity are only seen in rat hepatocytes. Is there a more physiological and simple way that can support clonal expansion of hepatocytes?

In partial hepatectomy model, many signaling molecules, including EGF, HGF, IL6, TNFα, insulin, bile acids, leptin, etc., increase rapidly in blood after the surgery. IL6 is a cytokine widely studied in inflammation. Strikingly, IL6 also plays a central role in liver regeneration. After partial hepatectomy, IL6 is rapidly produced by both Kupffer cells and hepatocytes. In IL6 knockout mice, liver regeneration delays accompanied by increased liver necrosis after partial hepatectomy, which could be corrected by IL6 treatment. IL6 knockout increases hepatocytes apoptosis following CCl4 treatment, whereas pretreatment with IL6 reduces liver injury and accelerates regeneration. Similar phenomena have also been observed in IL6 receptor deficient mice. Although many evidences support that IL6 promotes liver regeneration in vivo, whether it can be used to support long-term expansion of hepatocytes in vitro remain unclear.

Here, we report that IL6 could promote long-term expansion (>30 passages in ~150 days with theoretical expansion of ~10^35 times) of primary mouse hepatocytes in vitro, by converting hepatocytes into induced hepatic progenitor cells (iHPCs) which maintain the capacity of differentiation into hepatocytes. IL6 also supports the establishment of single hepatocyte-derived iHPC clones. Hepatocytes differentiated from these iHPCs could easily engraft and repopulate the whole liver of Fat^+/− mice. Further studies show IL6 mainly promotes the proliferation of diploidy hepatocytes. And a number of transcription factors, including Barx2, FoxM1, Elf3 and Mxd3, plays critical roles in IL6 induced hepatocytes proliferation.

**Results**

**IL6 promotes primary hepatocytes expansion in vitro**

Previous studies have shown that IL6 and TNFα are the most important inflammatory cytokines involved in liver regeneration in vivo. To test their effects on hepatocyte proliferation, we cultured hepatocytes in the classical hepatocyte culture medium (HCM, containing epidermal growth factor (EGF) and hepatocyte growth factor (HGF)) supplemented with IL6 or TNFα. Consist with the general notion, no proliferation of hepatocytes was observed in HCM at day 14 (Supplementary Fig. 1a, b). TNFα slightly promoted cell growth, while IL6 stimulated significant cell proliferation (Supplementary Fig. 1a, b). More concentrations of IL6 were tested, significant growth of primary hepatocytes could be observed with 0.1 ng/ml IL6, and growth reached a plateau at 3 ng/ml (Supplementary Fig. 1c, d). We passaged the hepatocytes in media containing 0.3–30 ng/ml IL6 at D14 and cultured them again in the same media with the same starting number, and only the higher concentrations (10 and 30 ng/ml) supported further rapid growth (Supplementary Fig. 1e). So, we used 30 ng/ml IL6 for further studies. The growth stimulating effect of IL6 could be blocked by IL6-growth (Supplementary Fig. 1e). So, we used 30 ng/ml IL6 for further studies. The growth stimulating effect of IL6 could be blocked by IL6-growth (Supplementary Fig. 1e). So, we used 30 ng/ml IL6 for further studies. The growth stimulating effect of IL6 could be blocked by IL6-growth (Supplementary Fig. 1e). So, we used 30 ng/ml IL6 for further studies. The growth stimulating effect of IL6 could be blocked by IL6-growth (Supplementary Fig. 1e). So, we used 30 ng/ml IL6 for further studies. The growth stimulating effect of IL6 could be blocked by IL6-growth (Supplementary Fig. 1e). So, we used 30 ng/ml IL6 for further studies. The growth stimulating effect of IL6 could be blocked by IL6-growth (Supplementary Fig. 1e). So, we used 30 ng/ml IL6 for further studies. The growth stimulating effect of IL6 could be blocked by IL6-growth (Supplementary Fig. 1e). So, we used 30 ng/ml IL6 for further studies. The growth stimulating effect of IL6 could be blocked by IL6-growth (Supplementary Fig. 1e). So, we used 30 ng/ml IL6 for further studies. The growth stimulating effect of IL6 could be blocked by IL6-growth (Supplementary Fig. 1e). So, we used 30 ng/ml IL6 for further studies. The growth stimulating effect of IL6 could be blocked by IL6-growth (Supplementary Fig. 1e). So, we used 30 ng/ml IL6 for further studies. The growth stimulating effect of IL6 could be blocked by IL6-growth (Supplementary Fig. 1e). So, we used 30 ng/ml IL6 for further studies. The growth stimulating effect of IL6 could be blocked by IL6-growth (Supplementary Fig. 1e). So, we used 30 ng/ml IL6 for further studies. The growth stimulating effect of IL6 could be blocked by IL6-growth (Supplementary Fig. 1e). So, we used 30 ng/ml IL6 for further studies. The growth stimulating effect of IL6 could be blocked by IL6-growth (Supplementary Fig. 1e). So, we used 30 ng/ml IL6 for further studies. The growth stimulating effect of IL6 could be blocked by IL6-growth (Supplementary Fig. 1e). So, we used 30 ng/ml IL6 for further studies. The growth stimulating effect of IL6 could be blocked by IL6-growth (Supplementary Fig. 1e). So, we used 30 ng/ml IL6 for further. The proliferating cells at D14 shown typical epithelial morphology with a high nucleus/cytoplasm ratio, which is a typical feature of HPCs. Comparing to freshly isolated hepatocytes, the cells cultured in IL6-HCM (D14) grow rapidly (Fig. 1c) and were highly positive for cell cycle markers Cyclin D1 and Ki67, and HPC markers Sox9 and Ck19, but the genes related to the functions of hepatocytes, including Albumin, Hnf4α, Cyp1a2 and Cyp2c9, were significantly reduced (Fig. 1d–f). So, these cells were named IL6-induced HPCs (IL6-iHPCs).

IL6-iHPCs (D14) could be differentiated into mature hepatocytes using a widely used hepatic maturation medium (HMM) with minor modifications (Fig. 1a). After culturing IL6-iHPCs (D14) in HMM for 7 days, the cells differentiate into typical mature hepatocyte morphology (Supplementary Fig. 3a), we named these cells as IL6-induced mature hepatocytes (IL6-iMHs). Immunofluorescence staining revealed that IL6-iMHs expressed low level of cell cycle markers CyclinD1 and Ki67, almost no HPC markers Sox9 and Ck19, and the genes highly expressed in mature hepatocytes including Hnf4α, Albumin, Cyp1a2 and Cyp2c9 were significantly increased to levels comparable to primary hepatocytes (Fig. 1d–f). Quantitative RT-PCR analysis also confirmed more HPC genes and cell cycle genes were upregulated in IL6-iHPCs (D14), but greatly reduced in IL6-iMHs, while the genes related to mature hepatocyte functions were all down-regulated in IL6-iHPCs (D14), but then upregulated in IL6-iMHs (Supplementary Fig. 3b). Periodic acid-Schiff (PAS) and indocyanine green (ICG) uptake assay also showed that IL6-iMHs possessed the mature hepatocytes functions (Fig. 1g). Taken together, we found that IL6 could reprogram primary hepatocytes into iHPCs with high proliferation ability, and the IL6-iHPCs could be differentiated into mature hepatocytes.

**Long-term expansion of IL6-iHPCs with full differentiation capacity**

To test whether IL6 can support long-term expansion of iHPCs, IL6-iHPCs were passaged every 5–7 days (~90% confluence). IL6-iHPCs could be passaged for more than 30 times and the cumulative cell number increased from 2.3 × 10^5 to about 1 × 10^40 in ~150 days without any apparent morphological changes (Fig. 2a, b and Supplementary Fig. 4a). Interestingly, the growth rate kept increasing till reach a plateau at passage 20 (P20) (Fig. 2c). So, the time between passages gradually reduce from 7 to 5 days. Immunofluorescence staining revealed that IL6-iHPCs at P5, P10, P20 and P30 showed stable and high expression of the cell cycle markers CyclinD1 and Ki67 and hepatic progenitor markers Sox9 and Ck19 (Supplementary Fig. 4b, c). IL6-iHPCs at all passages could be differentiated into cells with typical mature hepatocyte-like morphology, these cells were named as IL6-iMHs-P5, P10, P20 and P30, respectively (Fig. 2d and Supplementary Fig. 5a). PAS staining, ICG uptake, immunofluorescence staining of Albumin, Hnf4α, Cyp1a2 and Cyp2c9 showed that IL6-iMHs-P5, P10, P20 and P30 were very similar to primary hepatocytes in these aspects (Fig. 2d and Supplementary Fig. 5a, b). More genes related to mature hepatocytes functions were also highly expressed by IL6-iMHs (Supplementary Fig. 5c). Similar to primary hepatocytes, IL6-iMHs were able to secrete albumin, produce urea and metabolize drugs (Fig. 2e).

**Generation of iHPC clones from single hepatocyte with IL6**

To confirm that IL6-iHPCs were indeed arise from hepatocytes, but not existing progenitor cells, a lineage-tracing experiment was carried out. R26^R26R26 tdTomato+ mice, in which tdTomato expression is prevented by a loxpl-flanked STOP cassette, were crossed with the Albumin-Cre mice and the offspring (Alb-td-mice) would have the tdTomato expressing in all hepatocytes (td-Hepatocytes) specifically (Fig. 3a). Similar to our previous findings, td-Hepatocytes could also be reprogrammed into tdTomato+ IL6-iHPCs (IL6-td-iHPCs) (Supplementary Fig. 6a). Further, we successfully established three single td-Hepatocyte-derived IL6-iHPCs lines (IL6-td-iHPCs-clone-1, 2 and 3, from three
mice), indicating the powerful growth promotion effect of IL6. As expected, IL6-td-iHPCs-clones all possessed high proliferative capacity in IL6-HCM (Supplementary Fig. 6b–d) and were highly positive for cell cycle markers CyclinD1 and Ki67 and hepatic progenitor markers Sox9 and Ck19 (Supplementary Fig. 6e, f, i). These clones could also be differentiated into mature hepatocytes (IL6-td-iMHs-clone-1, 2 and 3) (Fig. 3b). The albumin and urea secretion (Fig. 3c), PAS staining, ICG uptake (Fig. 3d) and immunofluorescence staining of hepatic markers Albumin, Hnf4α, Cyp1a2 and Cyp2c9 showed that IL6-td-iMHs-clone-1, 2 and 3 were comparable to td-Hepatocytes (Fig. 3e, f and Supplementary Fig. 6g–i). Moreover, these IL6-td-iHPCs-clones could be passaged for at least 30 times (Supplementary Fig. 6j), and could still be differentiated into mature hepatocytes with high expression of Albumin and Hnf4α (Supplementary Fig. 6k).

For further characterization, transcriptomic comparison was carried out among primary hepatocytes, IL6-iHPCs-D3 (P0), IL6-iHPCs-D14 (P0), IL6-iHPCs from different mouse and different passages and the IL6-iMHs differentiated from them (Fig. 3g, h). The profiles of primary hepatocytes and IL6-iMHs were highly similar and they were grouped together. The IL6 treated cells, even only for 3 days, were...
In contrast, the body weight of Fah−/− mice before NTBC withdrawal were almost returned to normal after transplantation (Fig. 4b). Remarkably, 9 out of 11 Fah−/− mice receiving td-Hepatocytes, 10 out of 16 Fah−/− mice receiving IL6-td-iMHs, 17 out of 18 Fah−/− mice receiving IL6-IMHs-clone 1 survived for 2 months after NTBC withdrawal (Fig. 4c). Two months after transplantation, the livers receiving td-Hepatocytes, IL6-td-iMHs and IL6-td-iMHs-clone 1 were as normal as the Alb−/− mice and Fah−/− mice before NTBC withdrawal/transplantation (Fig. 4d and Supplementary Fig. 8a). IL6-td-iMHs and IL6-td-iMHs-clone 1 could repopulate about 95% of the liver, similar to td-Hepatocytes (Fig. 4d, e and Supplementary Fig. 8b). The highly increased serum levels of AST, ALT, ALP and total bilirubin after NTBC withdrawal were almost returned to normal after transplantation (Fig. 4f). The repopulated td-Hepatocytes, IL6-td-iMHs and IL6-td-iMHs-clone 1 in Fah−/− mice were almost 100% positive for Fah, Hnf4α and Albumin staining (Fig. 4g and Supplementary Fig. 8c, d). Interestingly, although IL6-iMHs were matured from IL6-iHPCs which were express the HPC and biliary epithelial cell marker Ck19, the repopulated IL6-td-iMHs were negative for Ck19, indicating no conversion of IL6-IMHs to biliary epithelial cells in vivo (Supplementary Fig. 8e). As previously reported, although hepatocytes appear histologically homogeneous, the liver lobule is actually organized into concentric zones, or rings, in which hepatocytes express different metabolic enzymes across the portal vein to central vein axis through which blood flows13. Typically, Glutamine synthetase (GS) is positive in pericentral hepatocytes and Arginase1 (Arg1) is positive in periportal hepatocytes14,15. Interestingly, the repopulated td-Hepatocytes, IL6-td-iMHs and IL6-td-iMHs-clone 1 expressed GS only in the pericentral region, and Arg1 only in the periporal region (Supplementary Fig. 8f, g), indicating that transplanted IL6-iMHs could be specified into GS or Arg1 positive hepatocytes according to the different zones they were.
located. The repopulated IL6-td-iMHs were isolated at D63 (Fig. 4a). As expected, these cells all express tdTomato (Supplementary Fig. 9a) without Ki67 and Ck19 staining, but were positive for PAS staining and all mature hepatocyte markers (Supplementary Fig. 9b–d). Moreover, these cells could still be induced to proliferate by IL6 (Fig. 4h, i).

We also tested whether the long-term cultured IL6-td-iMHs (P35, cultured in IL6-HCM for >150 days and then in HMM for another 7 days) and IL6-td-iMHs-clone-1 (P20, cultured in IL6-HCM for ~100 days and then in HMM for another 7 days) could also rescue Fah−/− mice. All of the Fah−/− mice receiving IL6-td-iMHs (P35) and IL6-td-iMHs-clone-1 (P20) survived for 2 months after NTBC withdrawal (Supplementary Fig. 10a). The livers were almost fully occupied by the td-iMHs (Supplementary Fig. 10b, c). The serum levels of AST, ALT, ALP and total bilirubin were also returned to normal after transplantation (Supplementary Fig. 10d). The repopulated IL6-td-iMHs were almost 100% positive for Albumin staining (Supplementary Fig. 10e), and expressed GS in the pericentral region, and Arg1 in the periportal region (Supplementary Fig. 10f, g). Taken together, these results indicate that IL6-iMHs have functions of mature hepatocytes and can fully repopulate the liver of Fah−/− mice after NTBC withdrawal and rescue these animals.

Diploid cells account for the main expansion population of IL6-iHPCs

Previous studies have shown that mononucleated and binucleated polyploid hepatocytes are found in all mammalian species36. It is still unclear the exact functional differences between diploid and polyploid hepatocytes, some studies have shown that these cells may behave...
Fig. 4 | IL6 derived iMHs repopulate livers of Fah−/− mice. a Schematic diagram of the experimental procedure: td-iMHs matured from IL6-expanded td-iHPCs (mixed population or single-cell clones) were transplanted into the liver of Fah−/− mice, and the repopulated td-iMHs were isolated again 8 weeks later and tested for 2nd round of expansion with IL6. b Body weight change of Fah−/− mice (no NTBC) receiving vehicle (Non-trans, n = 9 mice), primary td-hepatocytes (td-Hepa, n = 11 mice), IL6-td-iMHs (P10, n = 16 mice) and IL6-td-iMHs-cloned-1 (P10, n = 18 mice). Data are Means ± SEM. Statistical differences between two groups were analyzed from reports36,42,43, the percentage of diploid (2c), tetraploid (4c) and octaploid (8c) cells in fresh isolated hepatocytes were 4.20 ± 0.63%, 71.83 ± 2.23% and 23.11 ± 1.81%, respectively (Fig. 5a). Interestingly, after culturing in IL6-HCM for 14 days, although the number of 4c and 8c cells were also increasing, but not as fast as the 2c cells, and the percentage of 2c-hepatocytes increased from ~4% (D0) to ~30% (D14), while the percentage of 4c- and 8c-hepatocytes all decreased (Fig. 5b). The number of 2c-hepatocytes increased for ~40 times, and the number of 4c- and 8c-hepatocytes increased for only ~3 times. After serial differently in metabolism, regeneration, tumorigenesis and in response to damage7,14. So, we evaluated the proliferation ability of diploid and polyploid hepatocytes in IL6-HCM. Consist with previous reports16,18,19, the percentage of diploid (2c), tetraploid (4c) and octaploid (8c) cells in fresh isolated hepatocytes were 4.20 ± 0.63%, 71.83 ± 2.23% and 23.11 ± 1.81%, respectively (Fig. 5a). Interestingly, after culturing in IL6-HCM for 14 days, although the number of 4c and 8c cells were also increasing, but not as fast as the 2c cells, and the percentage of 2c-hepatocytes increased from ~4% (D0) to ~30% (D14), while the percentage of 4c- and 8c-hepatocytes all decreased (Fig. 5b). The number of 2c-hepatocytes increased for ~40 times, and the number of 4c- and 8c-hepatocytes increased for only ~3 times. After serial
passage, the percentage of the 2c-population kept increasing from ~40% (P1) to ~60% (P10), while the 4c-population decreased from ~45% (P1) to ~30% (P10) and the 8c-population dropped from 10% (P1) to 5% (P10) (Fig. 5c, d). These data strongly suggest that 2c-hepatocytes are the dominant population during IL6-induced proliferation. However, the ploidy of hepatocytes may change in different cell division stage and may reduce or increase via multipolar mitosis. To better evaluate the proliferation ability of 2c, 4c and 8c-hepatocytes, we sorted these cells with FACS and then cultured them separately in IL6-HCM (Supplementary Fig. 11). Microscopic observations revealed that nearly all 2c-hepatocytes were mononucleated, and only ~40% of 4c-hepatocytes and ~7% of 8c-hepatocytes were mononucleated, and rest of the cells were binucleated (Fig. 5e, f). After culturing in IL6-HCM for 14 days, 2c-hepatocytes (IL6-2c-iHPCs) exhibited the highest expanding ability, the cell number increased for ~30 times (Fig. 5g). And the number of 4c-hepatocytes (IL6-4c-iHPCs) increased ~3 times while no obvious proliferation was observed in 8c cells (Fig. 5g). We also observed the karyotypes at late passages of IL6-td-iHPCs (P46) and IL6-td-iHPCs-clone-1 (P20). These cells exhibited normal diploid karyotype (Supplementary Fig. 12a, b). In summary, 2c-hepatocytes account for the main expansion population in vitro culture with IL6-HCM.

Mechanisms underlying IL6-induced hepatocyte expansion

We have demonstrated in Supplementary Fig. 2e, IL6 in combination with either one of EGF or HGF was enough to convert primary hepatocytes into iHPCs for long-term expansion in vitro. But since EGF + HGF yielded best result and are commonly used in HCM, we will consider them as a whole in following study. A number of pathways, including JAK/STAT3, MAPK/ERK and PI3K/AKT have been reported to be strongly activated AKT and ERK1/2, but did not affect STAT3 pathway downstream of IL6, EGF and HGF. Western blotting revealed that during short-term treatment (within 6 h), IL6 strongly activated STAT3 and AKT, and slightly activated ERK1/2 pathway; while EGF + HGF strongly activated AKT and ERK1/2, but did not affect STAT3 pathway in hepatocytes (Fig. 6a). During hepatocytes cultured for 14 days in IL6-HCM (containing EGF + HGF), the STAT3 remained highly activated, while AKT was highly activated before Day 1 and maintained at a low activation level. Although the p-ERK1/2 remained at a high level at Day 14, but since total ERK1/2 increased along the time, the percent of activated ERK1/2 actually decreased (Supplementary Fig. 13a). Gene set enrichment analysis (GSEA) also demonstrated that there was a clear enrichment of genes related to IL6-JAK-STAT3 signaling in IL6-iHPCs (Day 14) comparing to primary hepatocytes (Day 0) (Supplementary Fig. 13b). Several pathway inhibitors, including JAK/STAT3 inhibitors...
Fig. 6 | Signal pathways and TFs involved in IL6-induced hepatocyte expansion.  
(a) Western blot analysis of STAT3, p-STAT3, AKT, p-AKT, ERK1/2, p-ERK1/2 in hepatocytes treated with IL6, EGF/HGF or the combination for 2, 4 and 6 h. GAPDH was used as loading control.  
(b) Cell numbers of hepatocytes cultured in IL6-HCM and a number of pathway modulators, including Cryotanshinone and BP-1-102 (JAK/STAT3 inhibitor), MK2206 and GSK2141795 (JAK/STAT3 inhibitor), PD0325901 (MARK/ERK1/2 inhibitor), and TGFβ1 for 14 days. Data are Means ± SEM (n = 4 independent experiments). **p < 0.01, ***p < 0.001 vs. first bar, *p < 0.05, **p < 0.01, ***p < 0.001 vs. second bar (two-tailed unpaired Student’s t test). Representative images (c) and cell number (d) of IL6-HPCs (P10) with combination knockdown of Barx2, Elf3, Mxd3 and FoxM1 expression in IL6-HCM. Data are Means ± SEM (n = 3 independent experiments).  
(e–g) Quantitative RT-PCR analysis of Barx2, Elf3, Mxd3 and FoxM1 in hepatocytes cultured in IL6-HCM for 14 days, and IL6-HPCs (P10). Data are Means ± SEM (n = 3 independent experiments).  
(h) Quantitative RT-PCR analysis of Barx2, Elf3, Mxd3 and FoxM1 in hepatocytes cultured in IL6-HCM for 14 days, and IL6-HPCs (P10). Data are Means ± SEM (n = 3 independent experiments).  
(i) Expression and cell number (right) of IL6-HPCs (P10) 5 days after transfection of shBarx2, shElf3, shMxd3, shFoxM1 or scramble sequence. Data are Means ± SEM (n = 3 independent experiments). **p < 0.01, ***p < 0.001 (two-tailed unpaired Student’s t test). Representative images (b) and cell number (f) of IL6-HPCs (P10) with combination knockdown of Barx2, Elf3, Mxd3 and FoxM1 in IL6-HCM. Data are Means ± SEM (n = 3 independent experiments). **p < 0.01, ***p < 0.001 (two-tailed unpaired Student’s t test).  
(j) Quantitative RT-PCR analysis of Barx2, Elf3, Mxd3 and FoxM1 expression in IL6-HPCs (P10) cultured in IL6-HCM with various pathway inhibitors (Cry, BP, MK, GSK and PD) for 5 days. Data are Means ± SEM (n = 3 independent experiments). **p < 0.01, ***p < 0.001 vs. first bar, *p < 0.05, **p < 0.01, ***p < 0.001 vs. second bar (two-tailed unpaired Student’s t test). Scale bars represent 100 μm. Source data and exact p values are provided in a Source data file.

Cryotanshinone (Cry) and BP-1-102 (BP), P38/JNK inhibitors MK2206 (MK) and GSK214179 (GSK), and MAPK/ERK1/2 inhibitor PD0325901 (PD), were all found to inhibit IL6-induced hepatocyte proliferation (Fig. 6b), indicating the combined activation of these pathways was necessary. TGFβ, an anti-proliferative factor in liver20, also blocked the proliferation (Fig. 6b).

Next, we sought to explore downstream transcription factors involved in IL6-induced hepatocyte proliferation. First line of evidence came from in vivo. After partial PHX, liver regeneration is impaired in the livers of IL6−/− mice21, indicating an important role of IL6 in liver regeneration. So, we evaluated the change of transcription factors in livers after PHX (PHX-6 h, 24 h, D3, D7 and D14). Comparing to normal liver, 115 transcription factors which were dramatically increased in PHX-6 h, 24 h or D3 and decreased to normal levels in PHX-D7 and D14 were picked out (Supplementary Fig. 14a, d, Group 1). On the other hand, comparing to primary hepatocytes, 361 transcription factors which were significantly increased in IL6-HPCs-D3, IL6-HPCs-D14, IL6-HPCs-mouse-1 (P10) and IL6-HPCs-mouse-2 (P10) were identified (Supplementary Fig. 14b, d, Group 2). Moreover, we also compared the transcription factors in IL6-HPCs-D7 and hepatocytes cultured in HCM (no IL6) for 7 days (HCM-Hepa-D7). Comparing to hepatocytes and HCM-Hepa-D7, 85 transcription factors which were dramatically increased in IL6-HPCs-D7 were picked out (Supplementary Fig. 14c, d, Group 3). At last, we compared the transcription factors in Group 1, 2 and 3, and 16 genes were identified (Supplementary Fig. 14d). The top 4 genes, including BARX Homeobox 2 (Barx2), E74-like factor 3 (Elf3),
Max dimerization protein 3 (Mxd3) and Forkhead box MI (FoxMI) were evaluated further (Supplementary Fig. 14e–g). Interestingly, FoxMI was recently reported to promote liver regeneration through a vagus-macrophage-hepatocyte link...44. Quantitative RT-PCR analysis showed that Barx2, Elf3, Mxd3 and FoxMI in hepatocytes were dramatically increased after cultured with IL6-HCM for 14 days and in IL6-iHPCs (P10) (Fig. 6c). Knockdown of Barx2, Elf3, Mxd3 or FoxMI in IL6-iHPCs (P10) using shRNA dramatically inhibited the growth (Fig. 6d–g). Knockdown of Barx2, Elf3, Mxd3 and FoxMI simultaneously, the IL6-iHPCs (P10) almost lost the growth capacity (Fig. 6h, i). Furthermore, in IL6-iHPCs cultured with pathway inhibitors Cry, BP, GSK, MK or PD for 5 days, Barx2, Elf3, Mxd3 and FoxMI were all dramatically decreased (Fig. 6j), indicating that Barx2, Elf3, Mxd3 and FoxMI were the common downstream of JAK/STAT3, MARK/ERK1/2 and PI3K/akt pathways. In conclusion, the JAK/STAT3, MAPK/ERK1/2 and PI3K/AKT pathways downstream of IL6, EGf and HGF all contribute to the reprogramming of hepatocytes into iHPCs and subsequent proliferation, and these pathways may regulate the growth of iHPCs via upregulation of transcription factors including Barx2, Elf3, Mxd3 and FoxMI.

Discussion

Adult hepatocytes have amazing proliferative capacity in liver but are very difficult to culture or expand in vitro. Here, we discovered that IL6, in combination with EGF and HGF, can support long-term (>30 passages in ~150 days with theoretical expansion of ~10⁴ times) expansion of hepatocytes in vitro in an easy 2D format by converting the hepatocytes into a progenitor state. IL6 also supports the establishment of single hepatocyte-derived iHPC clones. These IL6-iHPCs can be easily differentiated into mature hepatocytes, which can rescue Fah−/− mice after transplantation. This is a culture media very close to physiological conditions. IL6 at 0.1 ng/ml is enough to induce the growth of primary hepatocytes, while 10−30 ng/ml IL6 could support long-term culture. IL6 is typically very low in the serum, less than 1 pg/ml in mice and less than 100 pg/ml in humans. But after hepatectomy, serum IL6 can reach 4 ng/ml in mice43 and 0.7 ng/ml in human44, and the local concentration of IL6 in the liver might be even higher, since liver macrophages, including Kupffer cells, are the major source of IL641.

TNFs is another inflammatory cytokine that has been found to play a critical role in liver regeneration46. TNFα receptor knockout (TNFR-KO) or blocking TNFα with antibodies all impaired liver regeneration in mice or rat47,48. However, we found TNFα has limited potential in promoting hepatocyte growth in vitro. Akerman et al. have reported a potential role for TNFα in liver regeneration, they showed that TNFα blockade inhibited the increase in circulating levels of IL6 after PHX. Four hours after PHX, the IL6 mRNA decreased by more than ten-fold in the liver of TNFR-KO mice compared to wild-type mice49, and thus increases the expression of NFKB and STAT3 to DNA also failed to occur50. Moreover, the reduced hepatocyte replication and STAT3 binding in TNFR-KO mice could be completely corrected by injection of IL6. These results demonstrated a sequence of events for the initiation of liver regeneration: TNFα-NFKB-IL6-STAT3-DNA synthesis-regeneration. TNFα has been reported to regulate function and cytokine secretion of macrophages59,60. TNFα has also been found to activate NFKB pathway and IL6 production in Kupffer cells, which leads to STAT3 activation in hepatocytes. Combining these results with our observations, it is clear that TNFα promotes liver regeneration by enhancing IL6 production from macrophages and Kupffer cells, which in turn stimulate hepatocytes proliferation. This may explain why TNFα could induce hepatocytes proliferation in vivo but not in vitro.

We found in hepatocytes, IL6 mainly activates STAT3 pathway, while EGF/HGF mainly contribute to the activation of ERK and AKT pathways. Blocking any one of these pathways leads to failure of hepatocyte expansion, indicating a summation of these pathways is required. Here we identified a group of transcription factors regulated by the combination of STAT3, ERK and AKT pathways, downstream of IL6, EGF and HGF. The top ones being Barx2, Elf3, Mxd3 and FoxMI. Knockdown any of the four reduced the growth the IL6-iHPCs, while simultaneous knockdown of these genes totally blocked proliferation of iHPCs in IL6-HCM. Interestingly, a recent study has reported that FoxMI activation is involved in post-injury liver regeneration stimulated by the Vagus-macrophage-hepatocyte network. Compared to FoxMI, little is known about the other three TFs in hepatocytes proliferation or liver regeneration. Among them, Barx2, a member of the Bar class homeobox gene family, regulates transcription of specific cell adhesion molecules in the mouse. Barx2 has been reported to regulate bone growth and repair by regulating satellite cell proliferation and differentiation. Barx2 has also been reported to function as tumor suppressor in ovarian cancer. EGF is a member of the E-twenty-six family of transcription factors, has previously been implicated in the epithelial-mesenchymal transition in hepatocellular carcinoma. Upregulation of Elf3 has been found in NASH induced liver injury, and Elf3 has also been found to control the genes associating NASH induced reprogramming of hepatocytes to biliary-like hepatocytes. The role of Mxd3 on liver regeneration was rarely studied, but a study reports that Mxd3, as a member of Mad proteins family, is highly expressed in fetal liver and low in adult liver, suggesting a possible role of Mxd3 in hepatocyte proliferation. The exact roles of these genes in in vitro hepatocyte proliferation and in vivo liver regeneration need to be further studies.

Another interesting finding in our study is that the 2c-hepatocytes compose the major expanding population in the in vitro culture system. In adult liver, ~90% of rodent and 50% of human hepatocytes are polyploid61. Polyploid hepatocytes have been reported to have enhanced functions including metabolism, protein synthesis and secretion62,63. In liver regeneration, both diploid and polyploid hepatocytes contribute to liver regeneration64,65. However, it has been reported that diploid hepatocytes showed a proliferative advantage, entering and progressing through the cell cycle faster than polyploid cells, both in vitro and during liver regeneration after PHX. On the other hand, in various liver injury models, polyploid hepatocytes have also been found to reduce their ploidy during regeneration66. Single-cell analysis has shown that a subpopulation within the 2c-hepatocytes co-expresses the mature hepatocyte markers and HPC markers67. Diploid hepatocytes have also been reported to exhibit a stronger binding of insulin than polyploid cells, which is another important factor in liver regeneration. These studies indicate that both the diploid and polyploid hepatocytes can proliferate during liver regeneration. However, in IL6-induced hepatocyte growth in vitro, 2c cells seem to be the only population that can proliferate in long-term culture. After culturing in IL6-HCM for 14 days, the number of FACS-sorted 2c-cells increased for ~30 times (Fig. 5g). The number of FACS-sorted 4c cells only increased ~3 times, and the growth may come from the mixed small amount of 2c cells, which were at G2 stage and inseparable from 4c cells. No proliferation was observed in 8c cells (Fig. 5g), further indicating that 4c cells may not proliferate, since the 8c cells should also contain small amount of 4c cells at G2 stages. More careful studies need to be carried out to fully elucidate the differences observed in vivo and in vitro hepatocyte growth.

In conclusion, IL6 in combination with EGF and HGF can reprogram primary hepatocytes to iHPCs for long-term expansion without losing the maturation capacity in vitro. IL6-iMHs resemble primary hepatocytes in both gene expression profiles and functions, and can repopulate almost the whole liver of Fah−/− mice and rescue them. This physiological and simple way to expand primary hepatocytes in vitro may provide new ideas in culturing previously difficult-to-culture cell types and support their application in regenerative medicine.
Methods

All the experiments were compiled with international guidelines and were approved by the Ethics Committee of Shanghai Institute of Materia Media.

Mice

All mice were housed under controlled humidity (60 ± 10%) and temperature (22 ± 1°C) conditions and under 12-h light/dark cycles. The care and the use of animals were compiled with international guidelines and were approved by the Animal Ethics Committee of Shanghai Institute of Materia Media.

Isolation of mice primary hepatocytes

Mice (C57BL/6j) at the age of 8–10 weeks were used. Mouse hepatocytes were isolated using a standard two-step perfusion technique. In brief, the liver was perfused with 15 ml of perfusion buffer (NaCl 8000 mg/l, KCl 400 mg/l, NaH2PO4 600 mg/l, Na2HPO4 600 mg/l, NaHCO3 350 mg/l, EGTA 190 mg/l, Glucose 900 mg/l, pH 7.35–7.4) through the inferior vena at a flow rate of 3 ml/min, followed by 25 ml Enzyme buffer (NaCl 8000 mg/l, KCl 400 mg/l, NaH2PO4 600 mg/l, Na2HPO4 600 mg/l, NaHCO3 350 mg/l, CaCl2 2H2O 560 mg/l, HEPES 190 mg/l, Collagenase Type 1 (Gibco) 600 mg/l, pH 7.35–7.4) at the same flow rate. After perfusion, the liver was removed from the abdominal cavity and hepatocytes were released into the M199 medium supplemented with 10% FBS and 1% penicillin-streptomycin using sterile surgical scissors. Cell suspension was filtered through a 70 μm cell strainer (Corning). After centrifugation, hepatocytes were purified by 50% of percoll (Sigma) gradient at low-speed centrifugation (400 × g, 15 min) then the pellets were dissociated into single-cell suspension. Viability of isolated hepatocytes were about 90% as determined by Trypan blue staining. Finally, hepatocytes were seeded into gelatin-coated well plates at a density of 5 × 104/ml. Albumin-Cre mice (Jackson Laboratory, strain number: 007914) to generate mice with specific expression of tdTomato in hepatocytes. The offspring mice at the age of 8–10 weeks were used for lineage tracing experiments (Fig. 3a).

Generation and culture of IL6-iHPCs

After the primary hepatocytes adhered in 24-well plates for about 6 h, the medium was changed into IL6 expansion medium (IL6-HCM: DMEM/F12, 1 × ITS (Sigma), 20 ng/ml EGF (Sigma), 20 ng/ml HGF (Gibco), 10−5 M Dexamethasone (Sigma), 30 ng/ml IL6 (R&D Systems) and 1% penicillin-streptomycin). At day 14, the IL6-iHPCs were filtered through a 70 μm cell strainer (Corning). After lysis with PBS. Then, Nuclei were stained with Hoechst 33342 (10 g/ml) for 1 h. The slides were incubated with primary antibodies against α-Actinin (1:200; Bethyl, A90-234A), Hnf4α (1:200; Abcam ab161604), Cyp1a2 (1:200; Abcam ab22717), Cyp2c9 (1:200; Abcam ab4236), Fah (1:200; Genex GTX114400), GS (1:500; Abcam, ab49873), Arg1 (1:200; Abcam, ab96183). Secondary antibodies including Alexa Fluor 555 goat anti-mouse IgG (#A32727), Alexa Fluor 555 goat anti-rabbit IgG (#A32732), Alexa Fluor 488 rabbit anti-goat IgG (#A27012), Alexa Fluor 488 goat anti-mouse IgG (#A32723) and Alexa Fluor 488 goat anti-rabbit IgG (#A11034) were purchased from Invitrogen.

To analyze the glucose storage ability of primary hepatocytes and IL6-iMHs, cells were fixed by 4% PFA and stained with PAS kit (Sigma) according to the manufacturer’s instructions. The absorbance signals were measured with the EnSight™ multimode plate reader (PerkinElmer).

Cyp450 metabolism assay

To measure Cyp450 enzyme activity, primary hepatocytes and IL6-iMHs were cultured in HMM containing 100 μM testosterone for 24 h. Then, the supernatants were collected. Concentrations of the metabolites (acetaminophen, 4′-OH diclofenac and 6′-OH testosterone) in the supernatants were measured via liquid chromatograph-tandem mass spectrometer (Waters UPLC I-Class and Waters Xevo TQ-S mass spectrometer). All compounds were also purchased from Sigma-Aldrich and used as standard samples.

Assessment of anti-IL6 antibody

The primary hepatocytes or IL6-iHPCs (P5) were cultured in IL6-HCM and supplied with different concentrations of control IL6 neutralizing antibody (R&D Systems, MAB406-SP) or IgG (R&D Systems, 6-001-A) as shown in Supplementary Fig. 2a–d, the medium was changed for every other day.

Assessment of PI3K/AKT, ERK1/2, STAT3 pathways inhibitors and TGFβ1

The primary hepatocytes were cultured in IL6-HCM and supplied with different concentrations of chemicals or TGFβ1 (R&D Systems, 240-B-010) as shown in Fig. 6b. All chemicals were purchased from MedChemExpress, the medium was changed for every other day.

Immunofluorescence staining, PAS staining and ICG assay

Tissue slides were incubated in PBS containing 0.3% Triton X-100 and 5% BSA for 1 h. The slides were incubated with primary antibodies at 4 °C overnight. After thorough wash, slides were incubated with the appropriate fluorescein-conjugated secondary antibodies (1:500) for 1 h at room temperature. Finally, the cell nuclei were stained with Hoechst 33342 solution for 30 min. Cells were fixed in 4% PFA at room temperature for 30 min, then follow the same staining protocol as tissue slides. Images were captured with an Olympus IX71 inverted fluorescent microscope and analyzed by professional image analysis software (ImageJ).

The following antibodies were used in this study: CyclinD1 (1:200; Abcam ab134175), Ki67 (1:200; Cell Signaling Technology 9129S), Sox9 (1:200; Millipore ab5535), Cytokeratin 19 (1:200; Abcam ab52625), Albumin (1:200; Bethyl, A90-234A), Hnf4α (1:200; Abcam ab161604), Cyp1a2 (1:200; Abcam ab22717), Cyp2c9 (1:200; Abcam ab4236), Fah (1:200; Genex GTX114400), GS (1:500; Abcam, ab49873), Arg1 (1:200; Abcam, ab96183). Secondary antibodies including Alexa Fluor 555 goat anti-mouse IgG (#A32727), Alexa Fluor 555 goat anti-rabbit IgG (#A32732), Alexa Fluor 488 rabbit anti-goat IgG (#A27012), Alexa Fluor 488 goat anti-mouse IgG (#A32723) and Alexa Fluor 488 goat anti-rabbit IgG (#A11034) were purchased from Invitrogen.
Establishment of single hepatocytes derived IL6-iHPC clones

The single primary hepatocytes were pipetted under fluorescence microscope and seeded in one well of 96-well plates. After cultured in IL6-HCM for 14 days, the single primary hepatocytes derived IL6-iHPC clones were trypsinized and reseeded into new 12-well plate for further expanding.

Quantitative RT-PCR analysis

Total mRNA was isolated using Trizol (Invitrogen) and 1 μg RNA was reversed to cDNA using PrimeScriptTM RT reagent kit (Takara) according to the manufacturer’s protocol. Real-time PCR was performed using Hieff Qpcr SYBR Green Master Mix (Yeasen) and analyzed with a Stratagene Mx 3000P thermal cycler. Primers sequences are supplied in Supplementary Table 2.

Flow cytometry analysis of hepatocytes ploidy populations

Primary hepatocytes and IL6-iHPCs were fixed and permeabilized with Fixation/Permeabilization buffer (eBioscience™, 005123-43) for 20 min at 4 °C, then, the cells were incubated with 10 μg/mL propidium iodide (containing 0.2 mg/mL RNase) for 30 min at room temperature, then, cells were transferred into the 96-well plate through a 40 μm filter membrane, and then analyzed using a flow cytometer (ACEA Novocyt).

FACS sorting of 2c, 4c, 8c-hepatocytes

Primary hepatocytes and IL6-iHPCs were fixed and permeabilized with Fixation/Permeabilization buffer (eBioscience™, 4071IES10), the cells were analyzed using a FACS Aria III system (BD) as described in Supplementary Fig. 11 and sorted into 24-well collagen-coated plates for culture.

Karyotyping analysis

Cultured IL6-iHPCs in exponential growing phase were incubated with IL6-HCM containing 100 ng/ml colcemid for 3–4 h at 37 °C. Then, the cells were harvested via trypsinization and were treated with 0.075 M KCl at 37 °C for 30 min, and then fixed in methanol: acetic acid (3:1 ratio), with the solution changed two times. Finally, chromosomes were spread on slide glasses and stained with Giemsa staining solution (Gibco).

2/3 partial hepatectomy (2/3 PHx)

Mice (C57BL/6) at the age of 8–10 weeks were used for this experiment. 2/3 PHx operation was performed as previously reported. Adult mice were sacrificed at 6 h, 24 h, day 3, day 7 and day 14 to obtain liver tissues.

Bioinformatic analysis

RNA library for RNA-sequencing was prepared as follows: Firstly, total RNA was isolated using Trizol according to the manufacturer’s instructions. Secondly, mRNA was purified from total RNA and then was reverse-transcribed to cDNA for sequencing. Finally, after library preparation and pooling of different samples, the samples were subjected for Illumina sequencing using PE100 (paired-end 150nt) sequencing. Heatmap and correlation map were drawn by R software (v4.2.1, https://www.r-project.org). Genes with median absolute deviation (MAD > 2) were used for hierarchical clustering. GSEA was performed to identify the significantly enriched pathways of hepatocytes culturing with IL6 for 14 days. (Website: gsea-msigdb.org; Software: GSEA v4 desktop).

Western blot

Cells were lysed and homogenized in RIPA buffer supplemented with a protease inhibitor cocktail (Roche). Total protein was quantified using the BCA Protein Assay Kit (Thermo Fisher). Then protein extracts were boiled at 100 °C for 10 min in sample buffer (50 mM Tris-HCl, 2% w/v SDS, 10% glycerol, 1% β-mercaptoethanol, 0.01% bromophenyl blue (pH 6.8)). Cell lysates were separated on SDS-PAGE and transferred to polyvinylidene difluoride membranes. The membranes were first incubated with blocking buffer (TBS with 0.05% Tween 20, 10% nonfat milk) for 1 h at room temperature and then incubated overnight at 4 °C in buffer containing primary antibody. After thorough wash, cells were incubated with the appropriate HRP-conjugated secondary antibodies (1:10,000) for 1 h. Immunostaining was visualized using Amersham ECL Plus Western Blotting detection reagents (GE Healthcare) and ChemiDoc imaging system (Bio-Rad). The uncropped and unprocessed scans of the blots were provided in Supplementary Fig. 15.

Hematoxylin and eosin (H&E) staining

Liver samples were fixed in 4% paraformaldehyde (PFA), embedded in paraffin, and cut into 5 μm-thick sections. For H&E staining, sections were first stained with hematoxylin solution for 10 min, and then stained with eosin alcohol solution for 5 min. Finally, the sections were dehydrated and mounted with Permount Mounting Medium.

Hepatocyte transplantation and samples collection

All procedures for the care and the use of animals were complied with international guidelines and were approved by the Animal Ethics Committee of Shanghai Institute of Materia Media. *Fah<sup>−/−</sup>* mice (C57BL/6 background) at the age of 8–10 weeks were used for this experiment. Before transplantation, *Fah<sup>−/−</sup>* mice were fed with 7.5 mg/l NTBC in drinking water. For cell transplantation, according to previous reports, hepatocytes (2.5 × 10<sup>6</sup>) were suspend in 250 μl PBS and transplanted into *Fah<sup>−/−</sup>* mice via intrasplenic injection through a left-flank incision under 1.25% tribromoethanol anesthesia. After the operation, NTBC was withdrawn from the drinking water immediately. The blood and liver samples of *Fah<sup>−/−</sup>* mice transplanted with vehicle were collected at day 28. The blood and liver samples of *Fah<sup>−/−</sup>* mice transplanted with hepatocytes were collected at day 63. ALT, AST, ALP and TBIL were determined by commercial kits (BioAssay Systems) and a multimode plate reader.

Barx2, Elf3, FoxM1 and Mxd3 knockout in IL6-iHPCs (P10)

Short hairpin RNA (shRNA) targeting mouse Barx2, Elf3, FoxM1 and Mxd3 mRNA (Supplementary Table 3) were cloned into the PLKO.1/U6 plasmid. HEK293T cells were co-transfected with PLKO.1 (lenti-U6 plasmid) and the PLKO.1/U6 plasmid. Supernatants were collected 72 h after transfection. Lentiviral particles were filtered and stored at −80 °C until use. IL6-iHPCs (P10) were seeded in 24-well plates at a density of 2 × 10<sup>4</sup>/well. Then viral particles were infected the medium was changed to IL6-HCM for further culture. Efficiency was determined using qRT-PCR and cell counting later.

Statistical analysis

Values are reported as means ± SEM. p values were calculated by Student’s t test for two groups. To compare the curves for two groups, two-way ANOVA was performed in Figs. 1c, 4b, i and 5g. Survival was analyzed with Log-rank test in Fig. 4c and Supplementary Fig. 10a. p values <0.05 were considered statistically significant. All graphs were plotted with GraphPad Prism software (version 8.0.1).
The Immunofluorescence staining and positive cell percentage were analyzed using ImageJ software (version 1.46r).

Reporting summary
Further information on research design is available in the Nature Portfolio Reporting Summary linked to this article.

Data availability
The microarray data are available at the NCBI Gene Expression Omnibus with accession number GSE215423. Source data are provided with this paper.

References
1. Michalopoulos, G. K. & Bhushan, B. Liver regeneration: biological and pathological mechanisms and implications. Nat. Rev. Gastroenterol. Hepatol. 18, 40–55 (2021).
2. Gadd, V. L., Aleksieva, N. & Forbes, S. J. Epithelial plasticity during liver injury and regeneration. Cell Stem Cell 27, 557–573 (2020).
3. Michalopoulos, G. K. Liver regeneration: alternative epithelial pathways. Int. J. Biochem. Cell Biol. 43, 173–179 (2011).
4. Fausto, N. Liver regeneration and repair: hepatocytes, progenitor cells, and stem cells. Hepatology 39, 1477–1487 (2004).
5. Higgins, G. M. & Anderson, R. M. Experimental pathology of the liver I Restoration of the liver of the white rat following partial surgical removal. Arch. Pathol. 12, 186–202 (1931).
6. Zeilinger, K., Freyer, N., Damm, G., Seehofer, D. & Knospel, F. Cell sources for in vitro human liver cell culture models. Exp. Biol. Med. 241, 1684–1698 (2016).
7. Rombaut, M. et al. Direct reprogramming of somatic cells into induced hepatocytes: cracking the Enigma code. J. Hepatol. 75, 690–705 (2021).
8. Tarlow, B. D. et al. Bipotential adult liver progenitors are derived from chronically injured mature hepatocytes. Cell Stem Cell 15, 605–618 (2014).
9. Katsuda, T. et al. Conversion of terminally committed hepatocytes to culturable bipotent progenitor cells with regenerative capacity. Cell Stem Cell 20, 41–55 (2017).
10. Wu, H. et al. Reversible transition between hepatocytes and liver progenitors for in vitro hepatocyte expansion. Cell Res. 27, 709–712 (2017).
11. Peng, W. C. et al. Inflammatory cytokine TNFalpha promotes the long-term expansion of primary hepatocytes in 3D culture. Cell 175, 1607–1619.e1615 (2018).
12. Zhang, K. et al. In vitro expansion of primary human hepatocytes with efficient liver repopulation capacity. Cell Stem Cell 23, e804 (2018).
13. Fu, G. B. et al. Expansion and differentiation of human hepatocyte-derived liver progenitor-like cells and their use for the study of hepatotropic pathogens. Cell Res. 29, 8–22 (2019).
14. Hu, H. L. et al. Long-term expansion of functional mouse and human hepatocytes as 3D organoids. Cell 175, 1591–1606 (2018).
15. Kim, Y. et al. Adenine base editing and prime editing of chemically induced necrosis and apoptosis in mice by reducing MMP-2 expression. J. Hepatol. 42, 548–556 (2005).
16. Fazel Modares, N. et al. IL-6 trans-signaling controls liver regeneration after partial hepatectomy. Hepatology 70, 2075–2091 (2019).
17. Sekiya, S. & Suzuki, A. Direct conversion of mouse fibroblasts to hepatocyte-like cells by defined factors. Nature 475, 390–393 (2011).
18. Forbes, S. J. & Newsome, P. N. Liver regeneration – mechanisms and models to clinical application. Nat. Rev. Gastroenterol. Hepatol. 13, 473–485 (2016).
19. Michalopoulos, G. K. Hepatostat: liver regeneration and normal liver tissue maintenance. Hepatology 65, 1384–1392 (2017).
20. Taub, R. Liver regeneration: from myth to mechanism. Nat. Rev. Mol. Cell Biol. 5, 836–847 (2004).
21. Cressman, D. E. et al. Liver failure and defective hepatocyte regeneration in interleukin-6-deficient mice. Science 274, 1379–1383 (1996).
22. Norris, C. A. et al. Synthesis of IL-6 by hepatocytes is a normal response to common hepatic stimuli. PLoS ONE 9, e969053 (2014).
23. Kovalovich, K. et al. Increased toxic-induced liver injury and fibrosis in interleukin-6-deficient mice. Hepatology 31, 149–159 (2000).
24. Bansal, M. B. et al. Interleukin-6 protects hepatocytes from CCl4-mediated necrosis and apoptosis in mice by reducing MMP-2 expression. J. Hepatol. 42, 548–556 (2005).
25. Hu, H. L. et al. Long-term expansion of functional mouse and human hepatocytes as 3D organoids. Cell Res. 1624.e1615 (2021).
26. Taub, R. Liver regeneration: from myth to mechanism. Nat. Rev. Mol. Cell Biol. 5, 836–847 (2004).
27. Wang, F. et al. ABL1, overexpressed in hepatocellular carcinomas, regulates expression of NOTCH1 and promotes development of liver tumors in mice. Gastroenterology 159, 289–305.e16 (2020).
28. Grompe, M. et al. Loss of fumarylacetoacetate hydrolyase is responsible for the neonatal hepatic-dysfunction phenotype of lethal albino mice. Gene Dev. 7, 2298–2307 (1993).
29. Grompe, M. et al. Pharmacological correction of neonatal lethal hepatic-dysfunction in a murine model of hereditary tyrosinemia type I. Nat. Genet. 10, 453–460 (1995).
30. Guo, R. et al. Chemical cocktails enable hepatic reprogramming of mouse fibroblasts with a single transcription factor. Stem Cell Rep. 9, 499–512 (2017).
31. Huang, P. Y. et al. Induction of functional hepatocyte-like cells from mouse fibroblasts by defined factors. Nature 475, 386–U142 (2011).
32. Wang, X. et al. The origin and liver repopulating capacity of murine oval cells. Proc. Natl Acad. Sci. USA 100, 11881–11888 (2003).
33. Overtuft, K. et al. Hepatocytes corrected by gene therapy are selected in vivo in a murine model of hereditary tyrosinaemia type I. Nat. Genet. 12, 458–458 (1996).
34. Wei, Y. L. et al. Liver homeostasis is maintained by midlobular zone 2 hepatocytes. Science 371, 906 (2021).
35. Ben-Moshe, S. & Itzkovitz, S. Spatial heterogeneity in the mammalian liver. Nat. Rev. Gastro. Hepat. 16, 395–410 (2019).
36. Duncan, A. W. et al. The ploidy conveyor of mature hepatocytes as a source of genetic variation. Nature 467, 707–710 (2010).
37. Kreutz, C. et al. Hepatocyte ploidy is a diversity factor for liver homeostasis. Front. Physiol. 8, 862 (2017).
38. Matsumoto, T., Wakefield, L., Tarlow, B. D. & Grompe, M. In vivo lineage tracing of polyploid hepatocytes reveals extensive proliferation during liver regeneration. Cell Stem Cell 26, 34–47.e3 (2020).
39. Ovrebo, J. I. & Edgar, B. A. Polyploidy in tissue homeostasis and regeneration. Development 145, dev156034 (2018).
40. Sladky, V. C. et al. PIDDosome-induced p53-dependent ploidy restriction facilitates hepatocarcinogenesis. EMBO Rep. 21, e50893 (2020).
41. Wilkinson, P. D. et al. Polyploid hepatocytes facilitate adaptation and regeneration to chronic liver injury. Am. J. Pathol. 189, 1241–1255 (2019).
42. Matsuda, T. et al. Transcriptomic dissection of hepatocyte heterogeneity: linking ploidy, zonation, and stem/progenitor cell characteristics. Cell Mol. Gastroenterol. Hepatol. 9, 161–183 (2020).
43. Wilkinson, P. D. et al. The polyploid state restricts hepatocyte proliferation and liver regeneration in mice. Hepatology 69, 1242–1258 (2019).
44. Izumii, T. et al. Vagus-macrophage-hepatocyte link promotes post-injury liver regeneration and whole-body survival through hepatic FoxM1 activation. Nat. Commun. 9, 5300 (2018).

45. Sakamoto, T. et al. Mitosis and apoptosis in the liver of interleukin-6-deficient mice after partial hepatectomy. Hepatology 29, 403–411 (1999).

46. Sasturkar, S. V. et al. Serial changes of cytokines and growth factors in peripheral circulation after right lobe donor hepatectomy. Liver Transpl. 22, 344–351 (2016).

47. O’Neill, P. J. et al. Role of Kupffer cells in interleukin-6 release following trauma-hemorrhage and resuscitation. Shock 1, 43–47 (1994).

48. Akerman, P. et al. Antibodies to tumor necrosis factor-alpha inhibit liver regeneration after partial hepatectomy. Am. J. Physiol. 283, G579–G585 (1992).

49. Yamada, Y., Kirillova, I., Peschon, J. J. & Fausto, N. Initiation of liver growth by tumor necrosis factor: deficient liver regeneration in mice lacking type I tumor necrosis factor receptor. Proc. Natl Acad. Sci. USA 94, 1441–1446 (1997).

50. Gidon, A., Louet, C., Rost, L. M., Bruheim, P. & Flo, T. H. The tumor necrosis factor alpha and interleukin 6 auto-paracrine signaling loop controls mycobacterium avium infection via induction of IRF1/IRG1 in human primary macrophages. mBio 12, e0212121 (2021).

51. Parameswaran, N. & Patial, S. Tumor necrosis factor-alpha signaling by protecting ZEB1 from miR-141-3p-mediated silencing in hepato-cellular carcinoma. Oncogene 30, 6977–6981 (2021).

52. Meech, R. et al. BARX2 is expressed in satellite cells and is required for normal muscle growth and regeneration. Stem Cells 30, 253–265 (2012).

53. Stevens, T. A. & Meech, R. BARX2 and estrogen receptor-alpha (ESR1) coordinate the regulation of alternatively spliced ESR1 isoforms and control breast cancer cell growth and invasion. Oncogene 25, 5426–5435 (2006).

54. Zheng, L. B. et al. ELF3 promotes epithelial-mesenchymal transition by protecting ZEB1 from miR-141-3p-mediated silencing in hepatocellular carcinoma. Cell Death Dis. 9, 387 (2018).

55. Loft, A. et al. Liver-fibrosis-activated transcriptional networks govern hepatocyte reprogramming and intra-hepatic communication. Cell Metab. 33, 1685–1700.e9 (2021).

56. Sanders, J. A. & Gruppuso, P. A. Coordinated regulation of c-Myc and Max in rat liver development. Am. J. Physiol. Gastrointest. Liver Physiol. 290, G145–G155 (2006).

57. Sanders, J. A. & Gruppuso, P. A. Identification of transcriptional and metabolic programs related to mammalian cell size. Curr. Biol. 24, 598–608 (2014).

63. Mitchell, C. & Willenbring, H. A reproducible and well-tolerated method for 2/3 partial hepatectomy in mice. Nat. Protoc. 3, 1167–1170 (2008).

Acknowledgements This work was supported by grants from the Chinese Academy of Sciences (XDA16021308 to R.G., XDA16010202 to X.X.), the National Natural Science Foundation of China (82121005, 81730099 to X.X., 32000504 to R.G.), the China Postdoctoral Science Foundation (2018M642117 to R.G.). We thank the Molecular and Cell Biology Core Facility (MCBCF) at the School of Life Science and Technology, ShanghaiTech University for providing technical support for flow cytometry analysis.

Author contributions R.G., M.J., G.W. and B.L. conducted most of the experiments, analyzed the results, and wrote the paper; X.J., Y.A., S.C., P.T. and A.L. provided technical assistance for some cell experiments and critical discussions; Q.Y. provided technical support in animal study. R.G., M.J. and X.X. analyzed the results and wrote the paper. X.X. conceived the idea and supervise the study. All authors reviewed the results and approved the final version of the manuscript.

Competing interests The authors declare no competing interests.

Additional information Supplementary information The online version contains supplementary material available at https://doi.org/10.1038/s41467-022-35167-8.

Correspondence and requests for materials should be addressed to Xin Xie.

Peer review information Nature Communications thanks the anonymous reviewer(s) for their contribution to the peer review of this work.

Reprints and permissions information is available at http://www.nature.com/reprints.

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2022